5/16/2014 · The baseline characteristics of patients in PARADIGM-HF are presented for the first time today and will be published in the European Journal of Heart Failure (1). They reveal that compared to contemporary heart failure trials, the patients in PARADIGM-HF were particularly well treated, with the highest rate of beta-blockers (over 90%) and mineralocorticoid receptor antagonist (60%) use of any trial.
The 2019 ESC /EASD diabetes guidelines: a major paradigm shift in the management of T2DM 10′ education – Sep. 30, 2019 – Paris, France – Prof. Francesco Cosentino, MD New ESC /EASD Guidelines on diabetes no longer regard metformin as first-line therapy, 8/28/2019 · The findings were presented Sept. 2 at ESC Congress 2019 and simultaneously published in the Journal of the American Medical Association. While the clinical benefit of combined angiotensin receptor/neprilysin inhibitor (ARNI) therapy, vs. enalapril, was shown in the PARADIGM-HF study, the mechanism(s) for this benefit is unclear.
Results of PARADIGM -HF: a closer look session at Heart Failure 2015 / 2nd World Congress on Acute Heart Failure 2015 In order to bring you the best possible user experience, this site uses Javascript.
The study assessing LCZ696 ( PARADIGM -HF) met the primary endpoint showing reduced heart failure hospitalisations and reduced cardiovascular deaths. PARADIGM -HF , included 8,442 patients and was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current …
9/2/2019 · We know from the PARADIGM-HF trial—which was reported exactly 5 years ago at ESC Congress—that sacubitril/valsartan has outcome benefits in HFrEF.2 Added to that is the evidence showing that the combination reduced NT-proBNP levels more than valsartan alone from the phase II PARAMOUNT trial in HFpEF.3 The logical step was to investigate the effects of sacubitril/valsartan on …
